Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

•In previous analyses of GOG-86P, the addition of upfront bevacizumab to chemotherapy did not improve outcomes overall.•We now report that cases with mutations in the tumor suppressor TP53 experienced longer PFS and OS with bevacizumab.•OS with bevacizumab versus temsirolimus + chemotherapy doubled for cases with mutated TP53 (30 versus 14.4 months).•A mutation in TP53 is a potential biomarker for sensitivity to bevacizumab when added to chemotherapy upfront.